The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation
Abstract
Delivery of nucleic acids with positively charged lipid nanoparticles ((+)NPs) is widely used as research reagents and potentially for therapeutics due to their ability to deliver nucleic acids into the cell cytoplasm. However, in most reports little attention has been made to their toxic effects. In the present study, we performed comprehensive analyses of the potential toxicity associated with (+)NPs. Mice treated with (+)NPs showed increased liver enzyme release and body weight loss compared to mice treated with neutral or negatively charged NPs ((-)NPs), suggesting hepatotoxicity. Intravenous administration of (+)NPs induced interferon type I response and elevated mRNA levels of interferon responsive genes 15-25-fold higher than neutral and (-)NPs in different subsets of leukocytes. Moreover, treatment with (+)NPs provoked a dramatic pro-inflammatory response by inducing Th1 cytokines expression (IL-2, IFN gamma and TNF alpha) 10-75-fold higher than treatment with control particles. Finally, we showed that activation of TLR4 might serve as the underlying mechanism for induction of an immune response when (+)NPs are used. These results suggest that a careful attention must be made when different types of (+)NPs are being developed as nanotherapeutics.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cationic and ionizable lipids have also been reported to stimulate the secretion of pro-inflammatory cytokines and reactive oxygen species170–173.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [170]
In the citing paper
“Although the immunogenicity of these lipids has not yet been fully understood, complement system and Toll-like receptors may participate in innate immune activation170,173–175.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [170]
In the citing paper
“In vivo application of lipid nanoparticles has been reported to induce liver and lung injuries in rodents170,173, which may be attributed to the cytotoxicity of the materials and the induction of”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [170]
Citations
Cites
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
RNA interference is mediated by 21- and 22-nucleotide RNAsPreprint
Elbashir, S. M., Lendeckel, W., & Tuschl, T. (2001) · Genes & Development · doi:10.1101/gad.862301 · Cited by 3,354
Rational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822
RNAi-mediated gene silencing in non-human primates
Zimmermann, T. S., Lee, A. C. H., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M., et al. (2006) · Nature · doi:10.1038/nature04688 · Cited by 1,357
Interfering with disease: a progress report on siRNA-based therapeutics
de Fougerolles, A., Vornlocher, H., Maraganore, J. M., & Lieberman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2310 · Cited by 1,223
NanoGenotoxicology: The DNA damaging potential of engineered nanomaterials
Singh, N., Manshian, B. B., Jenkins, G. J. S., Griffiths, S. M., Williams, P. M., Maffeïs, T. G. G., Wright, C. J., & Doak, S. H. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.04.009 · Cited by 1,212
LPS, TLR4 and infectious disease diversity
Miller, S., Ernst, R. K., & Bader, M. W. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1068 · Cited by 1,059
Williams, D. F. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.07.027 · Cited by 971
Lipid-like materials for low-dose, in vivo gene silencing
Love, K. T., Mahon, K. P., Levins, C. G., Whitehead, K. A., Querbes, W., Dorkin, J. R., Qin, J., Cantley, W., Qin, L. L., Racie, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910603106 · Cited by 969
Cited by
Sorted by citations
Items 401–500 of 544
Emerging strategies in lymph node-targeted nano-delivery systems for tumor immunotherapy
Zhao, Y., Tian, M., Tong, X., Yang, X., Gan, L., & Yong, T. (2025) · Essays in Biochemistry · doi:10.1042/ebc20253008 · Cited by 7
Brar, H. K., Park, T., Dumo, C. J., Choi, P. J., Hwang, K., Nam, K. M., Kim, C., Dragunow, M., Wu, Z., Jose, J., et al. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01850-8 · Cited by 6
“Importantly, it is well known that excessively positively charged nanoparticles can cause significant systemic toxicity in vivo [56].”
The application of nanomaterials in vaccine adjuvants
Su, W., Yang, M., Huang, S., Huang, C., Li, Y., Wang, A., Wang, B., & Ding, X. (2026) · Nano Biomedicine and Engineering · doi:10.1016/j.nbe.2025.100038 · Cited by 6
In Vitro and In Vivo Evaluation of the Toxic Effects of Dodecylguanidine Hydrochloride
Lim, Y., Kim, H., Lim, S. K., Yoo, J., Lee, J., Eom, I., Yoon, B., Kim, P., Yu, S., & Shim, I. (2020) · Toxics · doi:10.3390/toxics8030076 · Cited by 6
Tehrani, S. F., Rabanel, J., Legeay, S., Cayon, J., Riou, J., Saulnier, P., Marleau, S., Roullin, G., Hildgen, P., & Bastiat, G. (2022) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2022.04.003 · Cited by 8
Advanced Theranostic Strategies for Viral Hepatitis Using Carbon Nanostructures
Gholami, A., Mousavi, S. M., Masoumzadeh, R., Binazadeh, M., Lankarani, K. B., Omidifar, N., Arjmand, O., Chiang, W., Moghadami, M., & Rumjit, N. P. (2023) · Micromachines · doi:10.3390/mi14061185 · Cited by 7
Gómez-Gaete, C., Ferreira, F., Bustos, P., Sigrid Mennickent, C., Castillo, D., Chávez, C., Novoa, P., & Godoy, R. (2018) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2018.1445263 · Cited by 6
“Although negatively charged NPs may face higher difficulties when considering cellular uptake, due to electrostatic repulsion from cellular membranes, these NPs presents advantages over their cationic counterparts, as they are expected to be less cytotoxic, as for cationic NPs there is risk of causing cell lysis by di…”
BackgroundTargeted Delivery of Nucleic Acid Therapeutics via Nonviral Vectors
Kapoor, M., & Burgess, D. J. (2014) · Advances in delivery science and technology · doi:10.1007/978-3-319-11355-5_8 · Cited by 6
RNA binding protein as monodisperse carriers for siRNA delivery
Wang, W., & Tai, W. (2019) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2019.100011 · Cited by 6
“…uptake and sometimes involve in endosome escape; on the other hand, the prosperity of positively charged surface induces some adverse effects including cationic toxicity, nonspeci fi c binding, complex formulation that make them recalcitrant to meet the rigorous demands of clinic utility [4,8,9].”
Cruz, Z., García‐Estrada, C., Olabarrieta, I., & Rainieri, S. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800350-3.00021-2 · Cited by 6
Delivery of genome editors with engineered virus-like particles
Lu, C., Li, Y., Cummings, J. R., & Banskota, S. (2025) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2025.01.007 · Cited by 8
CRISPR-Cas technologies: Emerging tools from research to clinical application
Hyeon, H., Hwang, S., Luo, Y., Shin, E., Yeom, J., Kim, H., Ryu, M., & Lee, K. (2025) · The Journal of Microbiology · doi:10.71150/jm.2504012 · Cited by 7
“Furthermore, LNP-based delivery is associated with dose-dependent toxicity and potential immunogenicity, which pose challenges to its therapeutic applicability (Kedmi et al., 2010; Swaminathan et al., 2016).”
Optimizing the targeting of lipid nanoparticles for gene therapy
Yue, L., Gao, X., Qi, W., Zhang, L., & Wang, Y. (2025) · Nanoscale Horizons · doi:10.1039/d5nh00351b · Cited by 6
Non-cationic carriers for siRNA delivery: Current progress and potential applications
Fan, M., Yang, X., Liu, Y., Xia, X., Ismail, M., & Zheng, M. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114362 · Cited by 5
Nano-Enabled Therapeutics: Novel Strategies for Preeclampsia Treatment
Huang, Y., Zhang, X., Li, X., & He, C. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s578148 · Cited by 6
“52 In contrast, polymer-based nanocarriers stand out for their design flexibility, enabling precise control over properties like degradation kinetics, charge, and functional groups through tailored chemical synthesis.”
Patra, S., Patra, D., & Dey, J. (2025) · Chemistry - An Asian Journal · doi:10.1002/asia.202500180 · Cited by 5
Mead, M. N., Seneff, S., Rose, J., Wolfinger, R. D., Hulscher, N., & McCullough, P. A. (2024) · International Journal of Vaccine Theory Practice and Research · doi:10.56098/w66wjg87 · Cited by 13
Delivery Aspects for Implementing siRNA Therapeutics for Blood Diseases
Dezfouli, S. A., Michailides, M. E., & Uludağ, H. (2024) · Biochemistry · doi:10.1021/acs.biochem.4c00327 · Cited by 5
Next Generation of Cancer Immunotherapy: Targeting the Cancer-Immunity Cycle with Nanotechnology
Ma, Y., & Cai, L. (2020) · Springer eBooks · doi:10.1007/978-981-15-5386-8_4 · Cited by 5
Nonviral Vehicles for Gene Delivery
Warga, E., Austin-Carter, B., Comolli, N. K., & Elmer, J. J. (2021) · Nano LIFE · doi:10.1142/s1793984421300028 · Cited by 5
Highly Toxic Nanomaterials for Cancer Treatment
Zoubi, M. S. A., Aljabali, A. A. A., & Pal, K. (2021) · Springer eBooks · doi:10.1007/978-3-030-67223-2_8 · Cited by 5
Fabrication of Nanostructured Surfaces Towards the Prevention of Hospital-Acquired Infection
Paikra, S. K., Bauri, S., & Mishra, M. (2024) · Journal of Cluster Science · doi:10.1007/s10876-024-02652-7 · Cited by 5
“The positively charged nanostructure can be easily uptake by the cells due to interaction with negatively charged cell membrane but cationic nanostructure also activates the immune response very fast as compared to neutral and anionic particles [ 213].”
The RNA delivery dilemma—lipid versus polymer nanoparticle platforms
Martins, C., Mitchell, M. J., Peer, D., Perrie, Y., Siegwart, D. J., Alonso, M. J., & Aparicio-Blanco, J. (2026) · Drug Delivery and Translational Research · doi:10.1007/s13346-026-02044-6 · Cited by 12
Self-citationEngineered MS2 Virus Capsids for Cellular Display of Peptide Antigens
Martin, H. S., Huang, P., Leifer, I. C., Pratakshya, P., & Francis, M. B. (2025) · ACS Chemical Biology · doi:10.1021/acschembio.5c00700 · Cited by 5
Li, Y., Zhang, M., Gu, J., He, Y., Zhou, M., & Lin, Y. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108960 · Cited by 4
Streiber, M., Schubert, U. S., & Traeger, A. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115023 · Cited by 7
Enhancing RNA inhibitory activity using clamp-G-modified nucleobases
Pradeep, S. P., Kumar, V., Malik, S., Slack, F. J., Gupta, A., & Bahal, R. (2024) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2024.102120 · Cited by 4
“61,62 We established that four arginine increase PNA cellular uptake with no cellular toxicity.”
Oligonucleotide‐Linked Lipid Nanoparticles as a Versatile mRNA Nanovaccine Platform
Im, S. H., Chung, Y., Duskunovic, N., Choi, H., Park, S., & Chung, H. J. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202401868 · Cited by 4
Optimization and evaluation of gastroresistant microparticles designed for siRNA oral delivery
Stalder, T., Koenig, N., Cornu, R., Laurent, G., Pellequer, Y., Jurin, F. E., Moulari, B., Martin, H., & Béduneau, A. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114588 · Cited by 4
Askarizadeh, A., Vahdat‐Lasemi, F., Karav, S., Kesharwani, P., & Sahebkar, A. (2024) · European Polymer Journal · doi:10.1016/j.eurpolymj.2024.113624 · Cited by 4
Nanocoding: Lipid Nanoparticle Barcoding for Multiplexed Single-Cell RNA Sequencing
Feng, Y., Chen, D., Applegate, C. C., Medina, N. G., Kuo, C.-W., Arogundade, O. H., Wright, C. L., Xu, F., Drnevich, J. M., & Smith, A. M. (2025) · ACS Nano · doi:10.1021/acsnano.5c02111 · Cited by 4
Encapsulation of herb extracts (Aromatic and medicinal herbs)
Vinceković, M., Jurić, S., Marijan, M., Viskić, M., Vlahoviček‐Kahlina, K., & Bandić, L. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822716-9.00008-1 · Cited by 4
Ongun, M., Lokras, A. G., Foged, C., & Thakur, A. (2022) · RNA technologies · doi:10.1007/978-3-031-08415-7_11 · Cited by 4
Martin, A. L., Homenick, C. M., Xiang, Y., Gillies, E. R., & Matsuura, N. (2019) · Langmuir · doi:10.1021/acs.langmuir.8b04051 · Cited by 4
Immune response to nanobiomaterials
Schreiber, A., & Witte, F. (2017) · Elsevier eBooks · doi:10.1016/b978-0-08-100963-5.00013-6 · Cited by 4
The Impact of Hyaluronic Acid Coating on the Cationic Niosomal Surface for Doxorubicin Delivery
Mazzotta, E., Romeo, M., Sacco, G., Benedittis, S. D., Qualtieri, A., Perrotta, I. D., & Muzzalupo, R. (2025) · Molecules · doi:10.3390/molecules30051148 · Cited by 3
“For instance, Kedmi et al. [25] reported that injecting cationic liposomes containing dioleoyl-3-trimethylammonium propane (DOTAP) induced higher in vivo hepatotoxicity and proinflammatory responses compared to neutral and negatively charged liposomes.”
Duran, T., Çine, N., Karaselek, M. A., Gül, N., Küççüktürk, S., Hatipoğlu, D., Ateş, M. B., Çalışkan, Ü., & Koçak, N. (2025) · Scientific Reports · doi:10.1038/s41598-025-08142-8 · Cited by 3
“Additionally, LNPs with a positive zeta potential, while potentially enhancing immunogenicity, may also trigger unwanted inflammatory responses, making the balance of zeta potential a critical factor in designing safe and effective formulations 41 .”
Liu, X., Wang, J., Borghi, A., Xiao, S., Caracciolo, G., Pozzi, D., Marchini, C., & Miceli, C. (2025) · Microplastics and Nanoplastics · doi:10.1186/s43591-025-00170-5 · Cited by 4
“As a speculative hypothesis, members of the Toll-like receptor family, particularly TLR4 and TLR2, may be involved, as they have been shown to recognize positively charged particles [70, 71].”
Biocompatibility and safety of nanobiomaterials
Arunachalam, P., Karuppiah, P., & Al-Dhabi, N. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821013-0.00014-3 · Cited by 4
Markov, O. V., Васильевна, С. А., Mohamed, I. S. E., Shmendel, E. V., Maslov, M. A., Oshchepkova, A. L., Brenner, E. V., Mironova, N. L., & Аркадьевна, З. М. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112542 · Cited by 3
Targeting Nanotherapeutics to the Tumor Microenvironment: How Accurately Can We aim?
Schroeder, A. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.56 · Cited by 3
Challenges in nonparenteral nanomedicine therapy
Praveen, G. L., Kalarikkal, N., & Thomas, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820466-5.00002-8 · Cited by 3
“It was demonstrated that natural polymer-based nanomedicines have enhanced therapeutic efficacy as a result of the prolonged systemic circulation, targeted drug delivery, and cellular uptake [33, 34].”
BackgroundEmerging Nanomaterials for Cancer Targeting and Drug Delivery
Pandian, S. R. K., Theivendren, P., Ravishankar, V., Pavadai, P., Sivakumar, V., Palanisamy, P., Murugesan, S., & Kunjiappan, S. (2022) · Nanotechnology in the life sciences · doi:10.1007/978-3-030-82918-6_14 · Cited by 3
Wojnilowicz, M., Lázničková, P., Ju, Y., Ang, C., Tidu, F., Bendíčková, K., Forte, G., Plebanski, M., Caruso, F., Cavalieri, F., et al. (2022) · Biomaterials Advances · doi:10.1016/j.bioadv.2022.213083 · Cited by 4
Effects of Celastrol-Enriched Peanuts on Metabolic Health and the Development of Atherosclerosis
Shi, J., Cheng, Y., Wang, C., Liu, M., Qu, M., Zhou, S., Chen, L., Li, X., Luo, J., Luo, Y., et al. (2025) · Nutrients · doi:10.3390/nu17091418 · Cited by 3
“However, shortcomings still exist in these studies, such as material instability, immunogenicity, and systemic toxicity [20,21].”
Tailoring drug and gene codelivery nanosystems for glioblastoma treatment
Silva, J., Basso, J., Mendes, M., Sousa, J., Pais, A. A. C. C., & Vitorino, C. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819666-3.00005-5 · Cited by 3
Yuan, Z., Luozhong, S., Li, R., Gu, W., Chen, Y., Bhashyam, D., Lai, R., & Jiang, S. (2025) · ACS Nano · doi:10.1021/acsnano.5c02001 · Cited by 6
Recent advances in gene delivery for melanocyte-associated disorders
Chhibber, T., Deacon, D. C., Ghandehari, H., & Judson‐Torres, R. L. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115703 · Cited by 3
Lipid‐Based Nanoplatforms in Hepatology: From Rational Design to Clinical Translation Challenges
Wang, J., Zhang, Q., Yang, L., Cheng, Z., Wang, C., Song, R., Dai, H., & Zhang, X. (2025) · MedComm – Biomaterials and Applications · doi:10.1002/mba2.70025 · Cited by 2
Feng, Y., Zhao, Y., Han, J., Li, F., Li, G., Wang, B., Chen, Q., & Song, J. (2026) · Nano Research · doi:10.26599/nr.2026.94908571 · Cited by 3
Tackling cancer stemness with nanotechnology in the era of precision medicine
Guo, S., Yao, S., Meng, L., Chen, C., Lu, Y. L., Lu, R., Zahid, K. R., Raza, U., Wu, Q., & Chen, W. (2026) · BMEMat · doi:10.1002/bmm2.70099 · Cited by 2
Philosof, N. R., Walsh, A. P. G., Xu, B., Watson, A. M. D., Ren, S., Hann, L., Nathaniel, B., Nguyen, A., Liu, H., Shi, P., et al. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102966 · Cited by 2
Ahn, J.-H., Lee, N.-Y., Bae, H.-J., Kim, J., Kwak, J., Kwon, E., Roh, G., Bae, S., Lee, S., Hwang, I. K., et al. (2026) · Toxicology Letters · doi:10.1016/j.toxlet.2026.111941 · Cited by 2
Biofate and cellular interactions of lipid nanoparticles
Baldim, I., OLIVEIRA, W. P. D., Rao, R., Raghuvir, S., Mahant, S., Gama, M., & Souto, E. B. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820757-4.00015-6 · Cited by 3
Identity crisis of nanostructures inside the human body: a perspective on inflammation
Saha, S., & Saso, L. (2023) · Frontiers in Nanotechnology · doi:10.3389/fnano.2023.1256952 · Cited by 3
Nanocarriers for Vaccine and Gene Delivery Application
Şenel, B., & Büyükköroğlu, G. (2018) · Advances in medical technologies and clinical practice book series · doi:10.4018/978-1-5225-4781-5.ch014 · Cited by 2
Regulatory aspects: Toxicity and safety
Banerjee, S., Chakraborty, U., Banerjee, S., Bose, S., Mondal, A., & Bishayee, A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-88450-1.00015-6 · Cited by 2
Toxicological impacts of nanomaterials on marine bivalves
Zha, S., Liu, H., Bao, Y., & Liu, G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19117-6.00008-8 · Cited by 2
Moura, C. C. (2013) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/p33k-8c45 · Cited by 2
Hoogenboezem, E. N., Patel, S. S., Cavnar, A. B., Lo, J. H.-J., Babb, L. M., Francini, N., Patil, P., Colazo, J. M., Michell, D. L., Sanchez, V. M., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.14.528574 · Cited by 2
“However, nanoparticle formulations are relatively complex to synthesize and are associated with injection reactions 2, 3 , necessitating premedication with corticosteroids and antihistamine, as in the case of patisiran 4 .”
Suppressor tRNA in gene therapy
Ruan, J., Yu, X., Xu, H., Cui, W., Zhang, K., Liu, C., Sun, W. A., Huang, X., An, L., & Zhang, Y. (2024) · Science China Life Sciences · doi:10.1007/s11427-024-2613-y · Cited by 2
Use of Nanotechnology in the Formulation of Vaccines
Perrie, Y., & Webb, C. (2024) · Springer eBooks · doi:10.1007/978-3-031-59478-6_18 · Cited by 1
Iterative Upgrading of mRNA Therapeutics by Modulating the Microenvironment for Translation
Shi, Y., Lou, Z., Wang, Y., Li, M., Wang, Y., & You, J. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202414722 · Cited by 1
Glycoluril Polymers for Codelivery in Solid Tumor Therapy
Wang, Y., Ren, X., Sun, Q., Yang, M., Wang, Y., Duan, J., Sun, Z., & Chen, Y. (2025) · Langmuir · doi:10.1021/acs.langmuir.5c01941 · Cited by 1
Wang, X., Liu, L., Chen, Y., Jia, L., Wang, Y., Jing, W., & Yan, G. (2025) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2025.100384 · Cited by 1
Iemitsu, K., Yoshii, K., Hirayama, Y., Liu, Z., Hifumi, S., Kondo, S., Ishida, K., Nagatake, T., & Kunisawa, J. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100956 · Cited by 1
Advanced in Co-Delivery, Controllable Therapy using Microneedle: From Design to Therapeutic Effects
Nguyen‐Thi, P., Nguyen, N. T. T., Le, H. T., Nguyen, T. T., & Vo, G. V. (2025) · Pharmaceutical Research · doi:10.1007/s11095-025-03995-0 · Cited by 1
“The positive charge of polymeric NPs could damage the cellular membrane and results in more toxicity to the patients and non-specific uptake in non-target cells in term of tumor treatment as well as more enzyme release in lipid-based NPs suggested for hepatotoxicity [100, 101].”
Biomedical Potential of Chitosan Nanoparticles: Advances in Drug Delivery and Disease Management
Srinivasan, M. K., Venkatesan, K. B., Jayaseelan, N., & Alamelu, S. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1010092 · Cited by 1
Recent progress in the rational design of mRNA vaccines
Guo, Z., Fu, J., Ran, L., Bao, N., Wang, Y., Dong, H., Yang, X., & Jin, Y. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.07.020 · Cited by 1
M6A-regulated LncRNA7825 maintains epithelial barrier integrity to restrict bacterial infection
Xu, H., Wu, X., Shi, L., Jiang, M., Wang, C., Guo, A., & Hu, C. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.117167 · Cited by 1
Takano, T., Matsumura, T., & Takahashi, Y. (2026) · International Immunology · doi:10.1093/intimm/dxag040 · Cited by 1
Accelerated discovery of thermostable mRNA–lipid nanoparticle vaccines using data-efficient AI
Tian, J., Tran, K. T. M., Pogostin, B. H., Sheridan, O., Mursalova, S., Lee, A. H., Liu, S., Hamkins, J., Antov, D., Power, A. L., et al. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03331-w · Cited by 1
Enhancing and Tailoring the Immunogenicity of Vaccines with Novel Adjuvants
Fox, C. B., Wizel, B., Reed, S. G., & O’Hagan, D. T. (2012) · Springer eBooks · doi:10.1007/978-3-7091-0709-6_3 · Cited by 1
Adjuvants, the Elephant in the Room for RNA Vaccines
D’haese, S., den Roover, S., & Aerts, J. L. (2022) · RNA technologies · doi:10.1007/978-3-031-08415-7_12 · Cited by 1
Gupta, S., Das, U. B., & Sinha, S. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.129017 · Cited by 1
Therapeutic targeting non-coding RNAs
Ray, R. M., Lazăr, A. D., Balahura, L.-R., Dobranici, A., Costache, M., & Dinescu, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-90406-3.00006-3 · Cited by 1
In vivo and in vitro toxicity of nanomaterials in animal systems
Shivaswamy, M. S., Yashkamal, K., & Shivakumar, M. S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15570-3.00014-4 · Cited by 1
Nanoparticles beyond the blood-brain barrier for glioblastoma
Jena, L., Dunne, N., & McCarthy, H. O. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821567-8.00027-0 · Cited by 1
Utilization of Chitosan for Gene Delivery
Oladele, J. O. (2023) · doi:10.1002/9781394175635.ch8 · Cited by 1
Emerging Cationic NanovaccinesPreprint
Carmona‐Ribeiro, A. M., & Pérez-Betancourt, Y. (2024) · Preprints.org · doi:10.20944/preprints202406.1292.v1 · Cited by 1
Neiman, G., Costa, M. W., Han, H., Zhao, S., Ng, T., Siemons, B. A., Nishino, T., Huang, Y., Jinagal, S. L., Wu, K. K.-Y., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.07.642075 · Cited by 1
“29, 30 We therefore assessed the action potential duration (APD) and contractile activity of the microtissues over time for 4 days, right before (D0) and after LNP delivery (D1-3).”
Gooding, M. (2011) · UCL Discovery (University College London)
Challenges and Opportunities in Bringing RNAi Technologies from Bench to Bed
Subramanya, S., & Ford, L. P. (2013) · doi:10.1002/9781118610749.ch3
Discovery and delivery of anti-angiogenic miRNAs for cancer treatment
Babae, N. (2013) · Utrecht University Repository (Utrecht University)
Detecting the environmental impact of nanoparticles using plant-based biosensors
Li, Y., Lenaghan, S. C., Burris, J. N., Stewart, C. N., Parker, L. E., & Zhang, M. (2011) · IEEE International Conference on Nanotechnology (IEEE-NANO) · doi:10.1109/nano.2011.6144505
“Most of the research thus far has focused on the toxicity of nanoparticles in mammalian systems, with little focus on the environmental impact in either the aquatic environment or on terrestrial plant species [4-7].”
BackgroundNanomedicines for Systemic Delivery of RNAi Therapeutics
Peer, D. (2012) · Advances in delivery science and technology · doi:10.1007/978-1-4614-4744-3_6
Self-citationNanotechnology toward Advancing Personalized Medicine
Sakamoto, J. H., Godin, B., Hu, Y., Blanco, E., van de Ven, A. L., Vellaichamy, A., Murphy, M. B., Francesca, S. L., Schuenemeyer, T., Given, B. D., et al. (2014) · Pan Stanford Publishing eBooks · doi:10.1201/b15465-2
Exploring extracellular vesicles for siRNA delivery and Raman-based diagnostics
Stremersch, S. (2016) · Ghent University Academic Bibliography (Ghent University)
Nanoparticle-Mediated RNA Interference for Cancer Therapy
Asai, T., Huang, L., & Oku, N. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-50878-0.00017-3
MicroRNA Nanocarriers for the Treatment of Chronic Obstructive Pulmonary Disease
Mohamed, A. (2018) · Liverpool John Moores University · doi:10.24377/researchonline.ljmu.ac.uk.00009376
Microfiber platform for oligodendrocyte myelination
Ong, W. (2019) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/136941
Lipid-coated Magnesium Phosphate Nanoparticles for Intrapulmonary Protein Delivery in Mice
Vadlamudi, M. (2019) · Scholarly Commons (University of the Pacific)
Niu, N., Shi, Z., Yang, Z., Li, Y., Shi, J.-D., Wang, Z., Liu, H., Ma, X.-M., & ding, H. (2020) · doi:10.21203/rs.3.rs-36126/v1
Yang, Z., Niu, N., Lou, C., Wang, X., Wang, C., & Shi, Z. (2022) · Research Square · doi:10.21203/rs.3.rs-1223038/v1
RNA delivery for cancer gene therapy
Öncül, S., Amero, P., Rodriguez‐Aguayo, C., Sood, A. K., Călin, G. A., & Lopez‐Berestein, G. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821595-1.00004-x
RNAi Nanomedicines toward Advancing Personalized Medicine
Peer, D. (2014) · Pan Stanford Publishing eBooks · doi:10.1201/b15465-3
Self-citationScott, E. A., & Allen, S. D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-08-102983-1.00017-x
Metadata
- Authors
- Kedmi, R., Ben-Arie, N., & Peer, D.
- Affiliations
- Tel Aviv University (IL)
- Corresponding author
- Peer, Dan
- Venue
- Biomaterials
- Publisher
- Elsevier BV
- Published
- 2010-09
- Volume
- 31
- Issue
- 26
- Pages
- 6867-6875
- ISSN
- 0142-9612 (ISSN-L)
- OpenAlex
- W2126020016
- Cited by
- 546
- References
- 52
- Citations by year
- 2026: 39 · 2025: 60 · 2024: 67 · 2023: 52 · 2022: 54 · 2021: 33 · 2020: 31 · 2019: 29 · 2018: 26 · 2017: 31 · 2016: 14 · 2015: 15 · 2014: 19 · 2013: 27 · 2012: 25
- FWCI
- 9.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Biomaterials (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Commission
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Keywords
- nanoparticle toxicity, TLR4, hepatotoxicity, inflammatory cytokines, Th1 response, nucleic acid delivery, nanotherapeutics, immune activation
- MeSH terms
- Animals, Immunity, Inflammation, Lipids, Mice, Inbred C57BL, Particle Size, Surface Properties, RNA, Small Interfering, Toll-Like Receptor 4, Mice, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
